| Jul 9 |
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial
|
| Jul 9 |
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
|
| Jul 8 |
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
|
| Jun 18 |
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
|
| Jun 17 |
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
|
| Jun 5 |
Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
|
